What drove the HLS.AX stock move after earnings?

HLS.AX stock moved on a mix of negative EPS **-0.78**, margin pressure in Pathology and Imaging, and higher-than-average volume **14,019,405.00**. Investors reacted to leverage and short-term guidance rather than cash flow strength.

What are realistic price targets for HLS.AX stock?

Realistic targets: conservative **A$0.60**, base **A$0.90**, upside **A$1.30**. These reflect the 50-day average **A$0.93**, 200-day average **A$0.86**, and the company’s year high **A$1.64**.

Does HLS.AX stock pay a dividend and is it sustainable?

Healius shows a dividend per share of **0.63**, but payout ratios and negative EPS reduce sustainability. Free cash flow exists, but high leverage and coverage ratios warrant caution.

How does Meyka AI view HLS.AX stock near term?

Meyka AI rates HLS.AX **68.81 (B) HOLD** and sees near-term upside to **A$0.85–A$0.92** if margins recover. The model highlights leverage and execution risk as key constraints.

AU Stocks

Pre-market ASX: HLS.AX Healius A$0.76 19 Feb 2026 earnings: Margin test

ByHuzaifa Zahoor February 19, 2026February 19, 2026

HLS.AX stock opens pre-market at A$0.76 after Healius Limited released earnings-related updates for 19 Feb 2026. The share price is down 4.40% from the prior close of A$0.80, with volume at 14,019,405.00 shares. Investors will watch margins in Pathology and Imaging after mixed top-line trends. We use Meyka AI-powered market analysis to link the results to valuation, cash flow metrics, and short-term price catalysts